Marksans Pharma Ltd. — Capital/Financing Update 2021

Nov 10, 2021

•• Marksans Pharma Ltd.

BSE Limited

Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404

National Stock Exchange of India Limited Listing Department Exchange Plaza, C-l, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051. Symbol: MARKSANS

Sub: Statement on Deviation or Variation of funds raised through Preferential Issue of Convertible Warrants.

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMDI/162/2019 dated December 24,2019, we hereby confirm that there is no deviation or variation in the use of funds raised through Preferential Issue of Convertible Warrants from the objects stated in the Explanatory Statement to the Notice of Extra-Ordinary General Meeting of the Company dated 15th June, 2021.

Accordingly, a Nil Statement of Deviation, duly reviewed by the Audit Committee of the Company, for the Quarter ended September 30, 2021 is given in "Annexure A".

Yours faithfully,

For Marksans Pharma Limited

ftiliM~ Harshavardhan Panigrahi Company Secretary

Marksans Pharma Ltd

11th FI.oor,"GRANDEUR", Opp. Gundecha S •. Andhen (W), Mumbai - 400 053 • Tel.: +91 Des,al.Extension Road, Oshiwara, 2~~g~~ioo~e:ra www .mar ksanspharma.comE-mail: Info@marksanspharmacom.

Statement	of Deviation / Variation	of Deviation / Variation	of Deviation / Variation	of Deviation / Variation	in	utilisation	utilisation	of funds raised
Name of listed enti						Marksans Pharma Limited
Mode of Fund Raisin						Preferential Issue
Date of Raisin Funds						20.07.2021
Amount Raised						Rs.	93,09,99,994
Re ort filed for uarter ended						30	Se	tember,2021
Monitorin A enc						Not	A	licable
Monitorin A enc Name	if a	licable				Not	A	licable
Is there a Deviation / Variation		in use of funds raised				No
If yes, whether the same is	pursuant		to change in terms			Not	Applicable
of a contract or objects, which was			approved	by the
shareholders
If Yes, Date of shareholder	A	roval				Not	A	plicable
Ex lanation for the Deviation / Variation						Not	A	plicable
Comments of the Audit Committee			after review			Nil
Comments of the auditors,	ifan					Nil

Objects for which funds have been raised and where there has been a deviation, in the following table

==> picture [458 x 257] intentionally omitted <==

----- Start of picture text -----

Original Object Modified Original Modifie Funds Amount of Remarks
Object, if Allocation d utilised till deviation/va if any
any allocati 30 [th] riation for
on, if September, the quarter
any 2021 according to
applicable
object
The proceeds of None Rs. None Rs. Nil No
the preferential 93,09,99,994 93,09,90,041 deviations
issue are proposed
to be used to
strengthen the
capital base and
to enhance long
term financial
resources of the
Company in order
to fund expansion
program of the
Company.
----- End of picture text -----

Deviation or variation could mean:

• (a) Deviation in the objects or purposes for which the funds have been raised or

• (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

==> picture [246 x 94] intentionally omitted <==

----- Start of picture text -----

For Marksans Pharma Limited
[~;]
L;:ttVV~ 'rtJ, J A'r Y_l/lA'. J .I.~ I fIJ MimjBA~3.?i•
fl. [\~]
~.y~~}j
~
-H-ar-s-h-av-ar-dh-a-n-P-an-igr-ah-i
Company Secretary & Compliance Officer
----- End of picture text -----